MARKET

MRKR

MRKR

Marker Therapeut
NASDAQ
4.320
-0.170
-3.79%
Closed 15:57 06/21 EDT
OPEN
4.410
PREV CLOSE
4.490
HIGH
4.445
LOW
4.020
VOLUME
15.17K
TURNOVER
0
52 WEEK HIGH
9.68
52 WEEK LOW
2.400
MARKET CAP
38.53M
P/E (TTM)
-6.7914
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MRKR last week (0610-0614)?
Weekly Report · 5d ago
Weekly Report: what happened at MRKR last week (0603-0607)?
Weekly Report · 06/10 11:01
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
EndRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% during the session. Agenus stock rose 11.54% and SILO Pharma shares declined by 34.7% in the same session.
Benzinga · 06/05 12:06
Weekly Report: what happened at MRKR last week (0527-0531)?
Weekly Report · 06/03 11:04
Weekly Report: what happened at MRKR last week (0520-0524)?
Weekly Report · 05/27 11:08
Weekly Report: what happened at MRKR last week (0513-0517)?
Weekly Report · 05/20 11:02
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024
Investorplace · 05/16 03:53
Marker Therapeutics, Inc. Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024
Press release · 05/16 03:52
More
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Webull offers Marker Therapeutics Inc stock information, including NASDAQ: MRKR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRKR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRKR stock methods without spending real money on the virtual paper trading platform.